Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis-Reference-Cited by-同舟云学术

Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis

Published:2021-12-27 Issue:1 Volume:27 Page:23-31
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Devos Timothy¹^ORCID,Selleslag Dominik²,Granacher Nikki³,Havelange Violaine⁴^ORCID,Benghiat Fleur Samantha⁵^ORCID

Affiliation:

1. Department of Hematology, University Hospitals Leuven (UZ Leuven) and Department of Microbiology and Immunology, Laboratory of Molecular Immunology (Rega Institute), Catholic University Leuven (KU Leuven), Leuven, Belgium

2. Department of Hematology, Algemeen Ziekenhuis Sint-Jan, Bruges, Belgium

3. Department of Hematology, Ziekenhuis Netwerk Antwerpen, Antwerp, Belgium

4. Department of Hematology, Cliniques universitaires Saint-Luc, Brussels, Belgium

5. Department of Hemato-Oncology, Erasme Hospital, Brussels, Belgium

Funder

Novartis

Publisher

Informa UK Limited

Subject

Hematology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/16078454.2021.2009645

Reference66 articles.

1. Myeloproliferative Neoplasms

2. Primary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management

3. The evolving treatment paradigm in myelofibrosis

4. Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice

5. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and validation of an LC-MS/MS method for ruxolitinib quantification: advancing personalized therapy in hematologic malignancies;Journal of Pharmacy & Pharmaceutical Sciences;2024-06-28

2. Disseminated tuberculosis mimicking pleural mesothelioma in a polycythemia vera patient treated with ruxolitinib;Pulmonology;2024-06

3. Enhancement of vincristine sensitivity in retinoblastoma through Janus kinase inhibition by ruxolitinib;Anti-Cancer Drugs;2024-05-10

4. The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis;Annals of Hematology;2024-03-18

5. Clinical and experimental treatment of primary humoral immunodeficiencies;Clinical and Experimental Immunology;2024-02-02